Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on June 3, 2022. The Company is incorporated in Nevada and maintains its principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The Nasdaq Stock Market LLC under the symbols "XBIO" and "XBIOW," respectively.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory compliance matter regarding the Company's stock listing status.
Material Changes and Listing Status
On June 3, 2022, the Company received a written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC. The notice stated that the closing bid price for the Company's common stock had been below $1.00 for 30 consecutive business days, resulting in non-compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement").
- Current Status: The notice has no immediate effect on the listing of the Company's common stock.
- Compliance Period: The Company has 180 calendar days from the date of the notice to regain compliance.
- Compliance Date: November 30, 2022.
- Requirement to Regain Compliance: The closing bid price must be at least $1.00 for a minimum of ten consecutive business days prior to the Compliance Date.
Outlook, Risks, and Management Commentary
The Company intends to monitor the closing bid price of its common stock and may consider available options to regain compliance, though no specific action plan was detailed in this filing. Management noted that there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or other Nasdaq Listing Rules.
If the Company fails to regain compliance by the Compliance Date, it may be eligible for an additional 180-day compliance period. To qualify for this second period, the Company must meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, potentially requiring a reverse stock split.
The filing includes standard forward-looking statements regarding risks such as general market factors, economic conditions, public health issues (including COVID-19), competitive product development, regulatory processes, and patent litigation.
Investor Verification Checklist
- Verify the current closing bid price of XBIO common stock to assess proximity to the $1.00 threshold.
- Monitor subsequent filings for announcements regarding a reverse stock split or other capital structure changes intended to cure the deficiency.
- Review the Company's most recent Form 10-Q or 10-K for liquidity and cash position, as this 8-K does not provide financial data.
- Track the Company's progress toward the November 30, 2022, compliance deadline.